174 related articles for article (PubMed ID: 32787284)
1. Therapeutic Efficacy of
Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
[TBL] [Abstract][Full Text] [Related]
3.
D'Huyvetter M; De Vos J; Xavier C; Pruszynski M; Sterckx YGJ; Massa S; Raes G; Caveliers V; Zalutsky MR; Lahoutte T; Devoogdt N
Clin Cancer Res; 2017 Nov; 23(21):6616-6628. PubMed ID: 28751451
[No Abstract] [Full Text] [Related]
4. Preclinical Targeted α- and β
Puttemans J; Dekempeneer Y; Eersels JL; Hanssens H; Debie P; Keyaerts M; Windhorst AD; van der Aa F; Lecocq Q; Breckpot K; Morgenstern A; Bruchertseifer F; Lahoutte T; Devoogdt N; D'Huyvetter M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326199
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
6. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
7. An Efficient Method for Labeling Single Domain Antibody Fragments with
Zhou Z; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioconjug Chem; 2018 Dec; 29(12):4090-4103. PubMed ID: 30384599
[TBL] [Abstract][Full Text] [Related]
8. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
[TBL] [Abstract][Full Text] [Related]
11. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of [
Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an
Feng Y; Meshaw R; McDougald D; Zhou Z; Zhao XG; Jannetti SA; Reiman RE; Pippen E; Marjoram R; Schaal JL; Vaidyanathan G; Zalutsky MR
Sci Rep; 2022 Feb; 12(1):3020. PubMed ID: 35194100
[TBL] [Abstract][Full Text] [Related]
15. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
16. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
17. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
18. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
20. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]